I-SPY 2 Helping To Normalize Adaptive Trial Designs
Executive Summary
Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.
You may also be interested in...
Precision Medicine: Despite Gains, Optimum Use Far From Reached
Progress has been made in areas such as lung and breast cancer, but panelists at a recent conference noted there are many efficiencies yet to be realized in drug development and reimbursement.
Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
I-SPY2 study shows promising efficacy for PD-1 inhibitor Keytruda in combination with chemo in high-risk breast cancer – including a tripling of response rate in triple-negative breast cancer – but also raises red flag on immune-mediated adverse events in early-stage patients.
Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening
Master protocol for Phase I/II screening trial could make development more efficient, but concerns about regulatory obligations, lack of registrational intent and infrastructure complexity – as well as firms' willingness to share – may be hurdles to participation.